Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Helix BioMedix, Inc. (OTC:HXBM), a developer of bioactive peptides, announced financial results for the third quarter ended September 30, 2009.
Laboratory Corporation of America® Holdings (NYSE:LH) announced William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, is scheduled to speak at the Credit Suisse 18th Annual Healthcare Conference in Phoenix AZ.
Oncolytics Biotech Inc. (NASDAQ:ONCY) announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.
PPD, Inc. (Nasdaq:PPDI) announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China.
Imagenetix, Inc. (OTC:IAGX), announced today that William Spencer, President and CEO of Imagenetix, will be presenting the Company's store at the 2nd annual LD MICRO Conference on Thursday, December 3rd, at 10:30 AM PST at the Luxe Sunset in Los Angeles.
Amarin Corporation plc (NASDAQ:AMRN) announced the appointment of John F. Thero as the Company’s Chief Financial Officer.
Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the Mass Technology Leadership Council, Inc. named Phase Forward Private Sector Company of the Year at the 2009 Mass Technology Leadership Awards in Boston last night.
BioSpecifics Technologies Corp. (Nasdaq:BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, announced its financial results for the third quarter ended September 30, 2009.
Caraco Pharmaceutical Laboratories, Ltd. (NYSE:CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration.
Stellar Pharmaceuticals Inc. (OTC:SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced its financial results for the third quarter ended September 30, 2009.
Cyberonics, Inc. (Nasdaq:CYBX) announced the company will report financial results for the second quarter ended October 23, 2009 of its fiscal year ending April 30, 2010 on Wednesday, November 18, 2009 at 5:00 PM EST.
GeoVax Labs, Inc. (OTC:GOVX), an Atlanta-based, biopharmaceutical company developing human vaccines for disease caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.
Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009.
Covidien (NYSE:COV), a leading global provider of healthcare products, announced the successful completion of its tender offer through its subsidiary, Transformer Delaware Corp., to purchase all of the outstanding shares of common stock of Aspect Medical Systems, Inc.
PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, announced Gregory S. Weisner, Chief Executive Officer, will make a presentation regarding the Company at the Credit Suisse 18th Annual Healthcare Conference in Phoenix, Arizona, on Wednesday, November 11, 2009, at 10:00 a.m. Mountain Time.
Ferro Corporation (NYSE:FOE) announced it has closed on its previously announced common stock offering. The total number of shares sold was 41,112,500, including 5,362,500 shares issued in connection with the exercise of the underwriters’ over-allotment option to purchase additional shares.
Boston Scientific Corporation (NYSE:BSX) announced it has reached an agreement in principle with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005.The alleged conduct and product sales occurred prior to Boston Scientific's 2006 acquisition of Guidant.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the remainder of 2009.
The Quigley Corporation, (Nasdaq:QGLY), www.quigleyco.com, announced it would issue its third quarter results at 8:30 AM (ET) on Thursday, November 12, 2009.
All News |
Breaking News |
Featured Stories